Toshi A Furukawa, Andrea Cipriani, Lauren Z Atkinson, Stefan Leucht, Yusuke Ogawa, Nozomi Takeshima, Yu Hayasaka, Anna Chaimani, Georgia Salanti
BACKGROUND: Previous studies have shown that placebo response rates in antidepressant trials have been increasing since the 1970s. However, these studies have been based on outdated or limited datasets and have used inappropriate statistical methods. We did a systematic review of placebo-controlled randomised controlled trials of antidepressants to examine associations between placebo-response rates and study and patient characteristics. METHODS: In this systematic review, we searched for published and unpublished double-blind randomised placebo-controlled trials of first-generation and second-generation antidepressants for acute treatment of major depression in adults (update: Jan 8, 2016)...
November 2016: Lancet Psychiatry
Judson A Brewer, Sarah Bowen, Joseph T Smith, G Alan Marlatt, Marc N Potenza
Both depression and substance use disorders represent major global public health concerns and are often co-occurring. Although there are ongoing discoveries regarding the pathophysiology and treatment of each condition, common mechanisms and effective treatments for co-occurring depression and substance abuse remain elusive. Mindfulness training has been shown recently to benefit both depression and substance use disorders, suggesting that this approach may target common behavioral and neurobiological processes...
October 2010: Addiction
André F Carvalho, Manu S Sharma, André R Brunoni, Eduard Vieta, Giovanni A Fava
Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment for major depressive disorders and are considered to be safer than tricyclic agents. In this critical review, we evaluated the literature on adverse events, tolerability and safety of selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran and vortioxetine. Several side effects are transient and may disappear after a few weeks following treatment initiation, but potentially serious adverse events may persist or ensue later...
2016: Psychotherapy and Psychosomatics
Mary Beth Connolly Gibbons, Robert Gallop, Donald Thompson, Debra Luther, Katherine Crits-Christoph, Julie Jacobs, Seohyun Yin, Paul Crits-Christoph
IMPORTANCE: Dynamic psychotherapy (DT) is widely practiced in the community, but few trials have established its effectiveness for specific mental health disorders relative to control conditions or other evidence-based psychotherapies. OBJECTIVE: To determine whether DT is not inferior to cognitive therapy (CT) in the treatment of major depressive disorder (MDD) in a community mental health setting. DESIGN, SETTING, AND PARTICIPANTS: From October 28, 2010, to July 2, 2014, outpatients with MDD were randomized to treatment delivered by trained therapists...
September 1, 2016: JAMA Psychiatry
Jerome Sarris, Jenifer Murphy, David Mischoulon, George I Papakostas, Maurizio Fava, Michael Berk, Chee H Ng
OBJECTIVE: There is burgeoning interest in augmentation strategies for improving inadequate response to antidepressants. The adjunctive use of standardized pharmaceutical-grade nutrients, known as nutraceuticals, has the potential to modulate several neurochemical pathways implicated in depression. While many studies have been conducted in this area, to date no specialized systematic review (or meta-analysis) has been conducted. METHOD: A systematic search of PubMed, CINAHL, Cochrane Library, and Web of Science was conducted up to December 2015 for clinical trials using adjunctive nutrients for depression...
June 1, 2016: American Journal of Psychiatry
Gordon Parker
OBJECTIVE: The objective of this study was to increase recognition of ultra-rapid metabolising status as a cause of treatment-resistant depression and consider management options. CONCLUSIONS: The incidence of ultra-rapid metabolising status is not rare in patients who fail to report improvement with antidepressant medication. Two broad options are available for identifying ultra-metabolising status. While there are several management options available to the clinician, combination therapy is likely of low utility while there are risks associated with mega-prescribing...
August 2016: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
Kenneth S Kendler
How should DSM criteria relate to the disorders they are designed to assess? To address this question empirically, the author examines how well DSM-5 symptomatic criteria for major depression capture the descriptions of clinical depression in the post-Kraepelin Western psychiatric tradition as described in textbooks published between 1900 and 1960. Eighteen symptoms and signs of depression were described, 10 of which are covered by the DSM criteria for major depression or melancholia. For two symptoms (mood and cognitive content), DSM criteria are considerably narrower than those described in the textbooks...
August 1, 2016: American Journal of Psychiatry
E Peña, M Mata, L López-Manzanares, M Kurtis, M Eimil, J C Martínez-Castrillo, I Navas, I J Posada, C Prieto, C Ruíz-Huete, L Vela, B Venegas
INTRODUCTION: Although antidepressants are widely used in Parkinson's disease (PD), few well-designed studies to support their efficacy have been conducted. DEVELOPMENT: These clinical guidelines are based on a review of the literature and the results of an AMN movement disorder study group survey. CONCLUSIONS: Evidence suggests that nortriptyline, venlafaxine, paroxetine, and citalopram may be useful in treating depression in PD, although studies on paroxetine and citalopram yield conflicting results...
March 19, 2016: Neurología
Joseph F Goldberg, Marlene P Freeman, Richard Balon, Leslie Citrome, Michael E Thase, John M Kane, Maurizio Fava
BACKGROUND: Optimal successive treatment decisions are not well established after an initial medication nonresponse in major depressive disorder or bipolar disorder. While practice guidelines offer consensus-based expert treatment recommendations, little is known about "real world" pharmacology decision making by practicing psychopharmacologists. MATERIALS AND METHODS: We surveyed via Internet the national membership of the American Society of Clinical Psychopharmacology (ASCP) to study preferred pharmacotherapy strategies and factors that influence medication choices for patients with mood disorders...
August 2015: Depression and Anxiety
Michael E Thase
No abstract text is available yet for this article.
January 26, 2016: JAMA
Sandeep Vaishnavi, Vani Rao, Jesse R Fann
BACKGROUND: Traumatic brain injury (TBI) is a significant public health concern. According to the Centers for Disease Control and Prevention, about 1.4 million people in the United States sustain a TBI annually. OBJECTIVE: This review places particular emphasis on the current knowledge of effective treatment of TBI symptoms, and proposes directions for future research. RESULTS: Neuropsychiatric problems are more prevalent and longer-lasting in TBI patients than in the general population...
2009: Psychosomatics
Michael E Thase
An array of antidepressant medications is available, but many patients do not achieve remission of their depressive episodes with initial treatment. Antidepressants differ in their mechanisms of action, with most of their therapeutic effects believed to be related to their effects on serotonin, norepinephrine, and/or dopamine. Depressive symptoms can vary greatly from patient to patient, and, therefore, different medications may be effective for one individual and not another. Clinicians can optimize treatment by selecting the antidepressant agent with the mechanism of action most likely to alleviate each patient's individual symptom profile...
December 2015: Journal of Clinical Psychiatry
Caroline Caddy, Ben H Amit, Tayla L McCloud, Jennifer M Rendell, Toshi A Furukawa, Rupert McShane, Keith Hawton, Andrea Cipriani
BACKGROUND: Considering the ample evidence of involvement of the glutamate system in the pathophysiology of depression, pre-clinical and clinical studies have been conducted to assess the antidepressant efficacy of glutamate inhibition, and glutamate receptor modulators in particular. This review focuses on the use of glutamate receptor modulators in unipolar depression. OBJECTIVES: To assess the effects - and review the acceptability - of ketamine and other glutamate receptor modulators in comparison to placebo (or saline placebo), other pharmacologically active agents, or electroconvulsive therapy (ECT) in alleviating the acute symptoms of depression in people with unipolar major depressive disorder...
September 23, 2015: Cochrane Database of Systematic Reviews
Ewgeni Jakubovski, Anjali L Varigonda, Nicholas Freemantle, Matthew J Taylor, Michael H Bloch
OBJECTIVE: Previous studies suggested that the treatment response to selective serotonin reuptake inhibitors (SSRIs) in major depressive disorder follows a flat response curve within the therapeutic dose range. The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder. METHOD: The authors searched PubMed for randomized placebo-controlled trials examining the efficacy of SSRIs for treating adults with major depressive disorder...
February 1, 2016: American Journal of Psychiatry
Trisha Suppes, Robert Silva, Josephine Cucchiaro, Yongcai Mao, Steven Targum, Caroline Streicher, Andrei Pikalov, Antony Loebel
OBJECTIVE: Accumulating evidence indicates that manic symptoms below the threshold for hypomania (mixed features) are common in individuals with major depressive disorder. This form of depression is often severe and is associated with an increased risk for recurrence, suicide attempts, substance abuse, and functional disability. This study evaluated the efficacy and safety of lurasidone in major depressive disorder with mixed features. METHODS: Patients meeting DSM-IV-TR criteria for major depressive disorder who presented with two or three protocol-defined manic symptoms were randomly assigned to 6 weeks of double-blind treatment with either lurasidone at 20-60 mg/day (N=109) or placebo (N=100)...
April 1, 2016: American Journal of Psychiatry
Jenny Guidi, Elena Tomba, Giovanni A Fava
OBJECTIVE: A number of randomized controlled trials in major depressive disorder have employed a sequential model, which consists of the use of pharmacotherapy in the acute phase and of psychotherapy in its residual phase. The aim of this review was to provide an updated meta-analysis of the efficacy of this approach in reducing the risk of relapse in major depressive disorder and to place these findings in the larger context of treatment selection. METHOD: Keyword searches were conducted in MEDLINE, EMBASE, PsycINFO, and Cochrane Library from inception of each database through October 2014...
February 1, 2016: American Journal of Psychiatry
Jennifer Wilkes
No abstract text is available yet for this article.
October 1, 2015: American Family Physician
Z G Laoutidis, K T Kioulos
INTRODUCTION: Desvenlafaxine, the active metabolite of venlafaxine, was approved in 2008 by the FDA for the treatment of depression. The aim of the present review is to provide an overview of the existing trials with desvenlafaxine and assess its overall efficacy and tolerability. METHODS: We searched in PubMed, EMBASE and the Cochrane Library for eligible studies (double-blind randomized control trials). A random effects model was used for the estimation of effect sizes...
September 2015: Pharmacopsychiatry
Daniel F Kripke
No abstract text is available yet for this article.
May 2015: Journal of Clinical Psychiatry
(no author information available yet)
No abstract text is available yet for this article.
July 15, 2015: American Family Physician
2015-07-31 05:29:04
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.